|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Eleven human lung cancer cell lines, including four derived from small cell lung cancer (SCLC) and seven derived from NSCLC were also examined for altered c-erbB-2 gene expression.
|
2569928 |
1989 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we tested for possible aberrations of the c-erbB-2 gene in the region of the transmembrane domain in surgical specimens of human primary lung cancer from 190 patients, and also examined 24 metastases and 26 specimens of noncancerous portions of the lung of the same patients.
|
1483946 |
1992 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer.
|
1350198 |
1992 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Southern blot analysis of DNA extracted from lung cancer cell lines detected amplification of both the topoisomerase II alpha and ERBB2 genes in the adenocarcinoma line Calu3.
|
1373318 |
1992 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the potential role of the c-erbB-2/neu gene in lung cancer metastasis systematically, we introduced the human c-erbB-2/neu gene into very low p185neu-expressing NCI-H460 human non-small cell lung cancer cells and then examined the experimental metastatic potentials among the parental NCI-H460 cells and stable transfectants with increased expression of p185neu.
|
7911396 |
1994 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have determined the average gene copy numbers (AGCN) of the erbB-1 gene, encoding the epidermal growth factor receptor (EGF-R), the erbB-2 and the erbB-3 genes in breast, ovarian, oral, and lung cancer tissue by using double-differential PCR (ddPCR).
|
7607571 |
1995 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Effective treatment of lung cancer cell lines growing as xenografts in nude mice was shown with Calu-3 (a lung adenocarcinoma line with high levels of p185(erbB-2) caused by gene amplification) and three other lung adenocarcinomas (A549, NCI-H1466, and 201T) with lower levels of p185(erbB-2) and no gene amplification.
|
9816093 |
1996 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since certain forms of lung cancer are also associated with overexpression of erbB-2, we evaluated the use of this novel therapeutic in this context.
|
8810638 |
1996 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, we conclude that systemic delivery of Ad.E1A(+) can efficiently achieve therapeutic effect in HER-2/neu-overexpressing lung cancer in vivo.
|
8875978 |
1996 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that a correlation between c-erbB-2 overexpression and tumorigenicity may exist in the Calu3 lung carcinoma cell line.
|
9259403 |
1997 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Molecular mechanisms altered in lung cancer include induced expression of oncogenes, such as RAS, MYC, c-erbB-2, and BCL-2, and loss of tumor-suppressor genes, such as RB, p53, and p16INK4A.
|
9508209 |
1998 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The biologic characteristics of the two human giant-cell lung carcinoma strains with high (strain D) and low metastatic potential (strain C) were studied, including karyotype of chromosome, intracellular free calcium ([Ca2+]i), morphologic changes of cell surface and the expression of nm23-H1, p53, ras, c-myc, c-erbB2, bcl-2 genes and PCNA.
|
10219898 |
1998 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERBB2 was amplified in bladder, breast, colon, stomach, testis, and lung cancer.
|
10473073 |
1999 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The frequencies of HLA B35, B52, B62, DRB1*0404, and DRB1*0406 were higher in the ErbB-2-positive lung cancer patients than in the ErbB-2-negative lung cancer patients.
|
10754210 |
2000 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We report the effect of heregulin beta1, the ligand for erbB-3 and erbB-4 receptors, on the regulation of vascular endothelial growth factor (VEGF) expression, using a panel of breast and lung cancer cell lines with constitutive erbB-2 overexpression or engineered to stably overexpress the erbB-2 receptor.
|
10918604 |
2000 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this report we evaluated Her-2/neu gene expression by fluorescence in situ hybridization (FISH) and the cell surface expression of the Her-2/neu receptor by immunohistochemistry using the HercepTest and by FACS analysis in 31 lung cancer cell lines with 5 breast cancer cell lines as controls.
|
11595720 |
2001 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We reviewed our experience with non-smokers who had CLL and subsequently developed lung carcinoma, in an effort to better understand the clinical course of these patients, and to evaluate the role of HER-2/neu overexpression.
|
11679181 |
2001 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biologic markers resulting from genetic lesions in lung cancer are grouped as follows: (a) oncogene amplification and overexpression (aberrant gene expression) and mutated tumor suppressor genes -- ras gene, myc gene, HER-2/neu and survivin gene, p53 and mutated beta-tubulin gene; (b) tumor biologic/radiobiologic factors -- tumor cell proliferation kinetics, hypoxia, intrinsic cellular radiosensitivity, gamma factor, and DNA content; (c) enzymes and hormones: neuron-specific enolase, serum lactate dehydrogenase, and enhanced glucose metabolic rate supported by increased glucose transporter protein.
|
11162866 |
2001 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraffin-embedded sections from 42 cases with lung carcinoma were stained immunohistochemically using the Avidin-Biotin Horseradish Peroxidase method to search for c-erbB-2 reaction.
|
11847606 |
2002 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Data regarding HER2/neu expression in lung cancer are more limited, and there is little information regarding HER2/neu expression and response to trastuzumab alone or in combination with chemotherapeutic agents.
|
12057039 |
2002 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
|
12173335 |
2002 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In lung cancer, the clinical significance of HER-2/neu expression is currently under evaluation.
|
11986780 |
2002 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Regarding HER-2/neu expression (gene or protein level) in lung cancer, several studies with inconsistent results have been recently reported, partially due to variable techniques used and/or heterogeneous populations examined.
|
14639106 |
2003 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, the frequency of a genetic aberration in the HER2 gene in lung cancer and the association between gene amplification and prognosis are poorly defined.
|
12455054 |
2003 |
|
Carcinoma of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Basal ErbB2 phosphorylation was identified in all lung cancer cell lines and was inhibited with an antibody that blocked the NRG-1 binding site on ErbB3.
|
14739033 |
2004 |